List of Excipients in Branded Drug PANTOPRAZOLE SODIUM D/R

« Back to Dashboard

Generic Drugs Containing PANTOPRAZOLE SODIUM D/R

Company	Ingredient	NDC	Excipient
Direct_Rx	pantoprazole sodium d/r	61919-700	CALCIUM STEARATE
Direct_Rx	pantoprazole sodium d/r	61919-700	CROSPOVIDONE
Direct_Rx	pantoprazole sodium d/r	61919-700	HYDROXYPROPYL CELLULOSE
Direct_Rx	pantoprazole sodium d/r	61919-700	HYPROMELLOSE 2910
Direct_Rx	pantoprazole sodium d/r	61919-700	MANNITOL
Direct_Rx	pantoprazole sodium d/r	61919-700	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER
Direct_Rx	pantoprazole sodium d/r	61919-700	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in PANTOPRAZOLE SODIUM D/R?

# Of NDCs	Excipient
1	CALCIUM STEARATE
1	CROSPOVIDONE
1	HYDROXYPROPYL CELLULOSE
1	HYPROMELLOSE 2910
1	MANNITOL
1	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER
1	PROPYLENE GLYCOL

Pantoprazole Sodium Delayed-Release Excipient Strategy and Commercial Opportunities

Last updated: October 4, 2026

Pantoprazole sodium delayed-release products are mature small-molecule medicines with limited opportunity for active-ingredient differentiation. Commercial value is concentrated in acid-protective formulation design, enteric-coating performance, manufacturing efficiency, stability control, and supply reliability. The strongest excipient opportunities involve low-moisture formulations, robust enteric coatings, simplified aqueous processing, and differentiated dosage forms such as delayed-release granules, orally disintegrating systems, and pediatric-compatible products.

What formulation does pantoprazole sodium delayed release require?

Pantoprazole is an acid-labile proton-pump inhibitor. The formulation must protect the active ingredient from gastric acid and release it in the higher-pH environment of the intestine. Delayed-release tablets and capsules therefore use an enteric-coated core, coated pellets, or enteric-coated granules. Immediate-release pantoprazole products are generally unsuitable because gastric exposure can degrade the active ingredient before absorption.

A typical product has four functional layers:

Formulation layer	Primary function	Common excipient classes
Drug-containing core	Disperse and stabilize pantoprazole sodium	Mannitol, microcrystalline cellulose, lactose alternatives, povidone, crospovidone, alkaline stabilizers
Seal coat	Separate the drug layer from acidic or aqueous coating components	Hypromellose, povidone, polyethylene glycol
Enteric coat	Prevent gastric release	Methacrylic acid copolymers, cellulose acetate phthalate, hypromellose phthalate
Outer coat or polishing layer	Improve appearance, handling and identification	Hypromellose, polyethylene glycol, titanium dioxide alternatives, iron oxides, talc

The reference Protonix delayed-release tablet label identifies a formulation architecture that includes an enteric coating and excipients such as mannitol, crospovidone, povidone, calcium stearate, hypromellose, propylene glycol, methacrylic acid copolymer, polysorbate 80, sodium lauryl sulfate, triethyl citrate, titanium dioxide and talc, although generic products may use different compositions (Wyeth Pharmaceuticals, 2012).

Which excipients are most important for pantoprazole stability?

Alkaline stabilization is the central excipient issue. Pantoprazole is more stable in an alkaline microenvironment than in an acidic one. Alkalizing agents, including sodium carbonate and related carbonate or bicarbonate systems, can protect the drug during granulation, storage and coating.

Alkaline stabilizers

Potential functions include:

• Raising the local pH around pantoprazole sodium
• Reducing acid-catalyzed degradation
• Limiting degradation during aqueous processing
• Improving long-term assay and related-substance profiles

The concentration must be optimized. Excess alkalinity can affect dissolution, coating adhesion, tablet hardness and compatibility with polymeric enteric coatings. Alkaline excipients also can increase sensitivity to moisture migration and local pH gradients within the dosage form.

Fillers and diluents

Mannitol is commercially attractive because it has low hygroscopicity, a clean sensory profile and good compatibility with direct-compression and granulation approaches. Microcrystalline cellulose can improve compactability but may contribute to moisture-related variability if the formulation is not adequately controlled.

Lactose can be used in some oral solid-dose products, but its use requires compatibility assessment with the selected grade of pantoprazole sodium and the manufacturing process. The selection should be based on impurity growth, water activity, compression performance and dissolution rather than cost alone.

Binders and disintegrants

Povidone supports granule formation and content uniformity. Crospovidone can accelerate tablet disintegration after the enteric coat dissolves. Sodium starch glycolate and croscarmellose sodium are possible alternatives, but they can change swelling behavior, coating stress and dissolution profiles.

The disintegrant must function without causing premature rupture of the enteric film. Excessive swelling may create coating defects, while insufficient disintegration can delay drug release after intestinal exposure.

What enteric-coating strategy is most suitable for pantoprazole?

A methacrylic acid copolymer is the most established commercial approach for pantoprazole delayed release. The polymer grade determines the pH threshold at which the film dissolves. The coating system should provide:

1. Low gastric release.
2. Rapid intestinal release after the target pH is reached.
3. Resistance to cracking during packaging, transport and storage.
4. Consistent performance after exposure to humidity.
5. Compatibility with alkaline drug cores.

Triethyl citrate is commonly used as a plasticizer for methacrylic acid copolymers. Talc can reduce tack and improve processing, while surfactants can improve coating dispersion and wetting. These materials also introduce process risks. Poor plasticizer distribution can cause brittle films, while excessive talc or surfactant can reduce film strength or affect dissolution.

Aqueous versus organic coating systems

Aqueous coating is commercially preferable where the polymer system supports it. It can reduce solvent-handling requirements, improve plant safety and simplify regulatory controls. The process may require tighter control of inlet temperature, spray rate, atomization, bed temperature and residual moisture.

Organic solvent systems can provide faster film formation and may be useful for difficult coating designs. They carry higher operational, environmental and validation burdens. A supplier that offers a ready-to-use aqueous enteric dispersion can capture value by reducing formulation development time and scale-up risk.

What excipient combinations offer the best commercial opportunity?

The most attractive opportunity is not a single excipient. It is a validated formulation package that addresses pantoprazole’s stability and delayed-release requirements.

Opportunity	Commercial value	Main technical barrier
Low-moisture alkaline core	Improves stability and shelf-life potential	Requires control of water activity and alkaline distribution
Ready-to-use enteric dispersion	Shortens development and scale-up	Must demonstrate dissolution equivalence
Co-processed filler-disintegrant system	Simplifies tablet manufacturing	May alter compression and release behavior
Solvent-free coating process	Reduces EHS and operating cost	Requires process optimization and film uniformity
Enteric-coated pellets	Enables capsule and sachet formats	More complex coating and content-uniformity controls
Pediatric granules	Expands age-group use	Taste, dose flexibility and unit-dose packaging
Titanium-dioxide-free coating	Supports market-specific excipient policies	Requires alternative opacity and color systems
Low-nitrite excipient supply	Reduces impurity concerns	Requires supplier qualification and lot monitoring

Low-nitrite and low-peroxide excipient programs have broader relevance across pharmaceuticals because reactive impurities can contribute to drug degradation or formation of potentially controlled impurities. The value proposition is strongest when the supplier provides documented impurity specifications, change-control discipline and multi-site supply.

What dosage forms are protected by pantoprazole formulation know-how?

Delayed-release tablets

Tablets are the lowest-cost commercial format and remain the dominant opportunity for generic competition. Differentiation depends on tablet size, coating efficiency, packaging, batch yield and dissolution robustness. A compact tablet can improve swallowing and reduce packaging costs, but high drug loading and alkaline excipients can complicate compression.

Delayed-release capsules

Capsules can contain enteric-coated pellets or granules. This approach supports flexible dose strengths and can simplify dose administration for patients who cannot swallow tablets. The tradeoff is higher manufacturing complexity and greater sensitivity to pellet-size distribution, capsule fill weight and moisture protection.

Oral granules and sachets

Granules may offer commercial value in pediatric, geriatric and hospital channels. The product must maintain enteric protection after reconstitution or administration with soft food. Taste masking is important because pantoprazole and alkaline stabilizers can produce an unpleasant sensory profile.

Orally disintegrating products

An orally disintegrating tablet cannot expose pantoprazole directly to saliva and gastric fluid. The active ingredient therefore must be protected in enteric-coated particles or microgranules. The technology is feasible but requires control of mouthfeel, particle rupture, coating integrity and rapid dispersion.

What is the FDA regulatory status of pantoprazole sodium delayed release?

Pantoprazole sodium delayed-release tablets and oral products are approved prescription medicines in the United States. The reference product, Protonix, was approved through a new drug application, while subsequent products generally rely on the abbreviated new drug application pathway and must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements (U.S. Food and Drug Administration, 2023a).

Pantoprazole delayed-release products are small-molecule medicines, not biologics. Biosimilar risk does not apply. The relevant competitive threat is generic substitution through ANDA approvals.

FDA review focuses on:

• Active-ingredient identity and strength
• Dosage-form equivalence
• Delayed-release dissolution
• Stability and impurity control
• Bioequivalence
• Manufacturing controls
• Container-closure protection from moisture
• Labeling and allowable inactive ingredients

The FDA Inactive Ingredient Database can support excipient precedent analysis, but prior use does not eliminate the need to justify the amount, route, dosage form and product-specific performance of each excipient (U.S. Food and Drug Administration, 2023b).

What is the Orange Book status and patent position for pantoprazole delayed release?

Pantoprazole is a mature active ingredient. The original compound and early product-protection period have expired in the United States, and generic products are established. The commercial issue is therefore not basic molecule exclusivity but whether a particular branded or generic product has active formulation, method-of-use or manufacturing patents listed in the FDA Orange Book.

Orange Book analysis must be performed by reference product, dosage form, strength and current listing status. Formulation patents can cover enteric-coated particles, specific release profiles, coating compositions or manufacturing methods. Such patents do not automatically prevent competition across the entire pantoprazole market.

Paragraph IV risk is generally product-specific. A generic applicant may certify that a listed patent is invalid, unenforceable or not infringed. The resulting litigation and potential 30-month stay depend on the patent listing, certification date and litigation history under the Hatch-Waxman framework (U.S. Food and Drug Administration, 2024).

When does pantoprazole lose exclusivity and how does generic entry affect pricing?

Pantoprazole has already passed the primary loss-of-exclusivity phase in the U.S. Generic entry has shifted competition toward manufacturing cost, supply continuity and channel access. The commercial consequences include:

• Lower average selling prices for standard tablets
• Greater purchasing pressure from wholesalers and hospital systems
• Reduced value of undifferentiated excipient formulations
• Higher value for reliable supply and rapid technology transfer
• More opportunity in private-label, contract-manufacturing and international markets

A new pantoprazole product is unlikely to command a premium solely through a different filler or coating polymer. A premium case requires a measurable advantage, such as a smaller tablet, stronger moisture stability, pediatric usability, fewer manufacturing steps or a differentiated regulatory package.

Which companies are challenging pantoprazole products?

Competition is fragmented across multinational generic manufacturers, regional pharmaceutical companies, contract development and manufacturing organizations, and private-label suppliers. A complete company-by-company litigation assessment cannot be assigned to "pantoprazole sodium delayed release" without limiting the analysis to a specific reference product, jurisdiction and time period.

The competitive landscape is generally divided into:

Segment	Competitive basis
Large generic manufacturers	Scale, procurement and broad distribution
Regional manufacturers	Local registration and tender access
CDMOs	Formulation development, coating and technology transfer
Excipient suppliers	Polymer systems, stabilizers and process support
Private-label companies	Channel relationships and low-cost supply

Licensing opportunities are most credible where an excipient supplier combines formulation know-how with a ready-to-file composition, validated coating process and regulatory documentation. A simple excipient resale agreement is less defensible than a package covering formulation, process parameters, analytical methods and technical support.

What manufacturing and intellectual-property barriers remain?

The principal manufacturing barriers are:

• Uniform distribution of alkaline stabilizer
• Protection of pantoprazole during wet processing
• Enteric-film continuity
• Control of gastric-stage release
• Rapid intestinal-stage release
• Moisture ingress during storage
• Coating scale-up from laboratory equipment to commercial pans
• Supply consistency for polymers and plasticizers

Potentially protectable technical elements include specific core compositions, coating-layer sequences, particle-size distributions, curing conditions and dissolution profiles. Patent strength depends on claim breadth, prior art, enablement, freedom-to-operate and the ability to detect infringement. Broad claims covering generic enteric coatings are vulnerable to prior art. Narrow claims tied to defined compositions or process conditions may be stronger but easier to design around.

How does pantoprazole compare with other proton-pump inhibitors?

Pantoprazole competes with omeprazole, esomeprazole, lansoprazole and rabeprazole. All require protection from gastric degradation, but their formulation and impurity profiles differ.

Product	Core formulation issue	Commercial implication
Pantoprazole sodium	Acid sensitivity and alkaline stabilization	Strong fit for enteric-coated tablets and pellets
Omeprazole	High sensitivity to acidic conditions	Extensive generic and OTC competition
Esomeprazole	Similar acid-protection requirements	Differentiation through formulation and brand positioning
Lansoprazole	Enteric protection and taste considerations	Opportunity in orally disintegrating formats
Rabeprazole	Acid protection and stability control	Smaller but technically similar formulation market

Pantoprazole’s opportunity is strongest in reliable, low-cost delayed-release products rather than molecule-level differentiation.

What commercial opportunities exist for excipient suppliers?

The most actionable opportunities are:

1. Supply ready-to-use methacrylic acid copolymer dispersions.
2. Provide alkaline core systems optimized for pantoprazole stability.
3. Develop low-moisture, direct-compression excipient platforms.
4. Offer titanium-dioxide-free and solvent-free coating systems.
5. Package excipient systems with formulation-development support.
6. Support pediatric granule and sachet development.
7. Provide multi-source supply and regulatory change-control documentation.
8. Build impurity-monitoring programs for nitrites, peroxides, metals and residual solvents.
9. License coating and pelletization processes to regional manufacturers.
10. Target emerging markets where reliable generic supply remains fragmented.

Revenue exposure is concentrated in high-volume generic tablets. Specialty formats can offer better margins but require stronger clinical usability, regulatory and manufacturing justification.

Key Takeaways

• Pantoprazole sodium delayed release depends on acid protection and alkaline stabilization.
• Enteric-coated tablets and pellets are the principal commercial dosage forms.
• Mannitol, povidone, crospovidone, alkaline stabilizers and methacrylic acid copolymers are key excipient classes.
• Ready-to-use aqueous coating systems and low-moisture core technologies offer the clearest supplier opportunities.
• Pantoprazole is a mature small molecule with generic competition; biosimilar risk does not apply.
• Patent value is product-specific and increasingly concentrated in formulation, process and method-of-use claims.
• Differentiation requires measurable advantages in stability, manufacturability, patient usability or regulatory execution.
• The strongest licensing model combines excipients with formulation know-how, analytical methods and scale-up support.

FAQs

Can pantoprazole sodium delayed release use enteric-coated pellets?

Yes. Enteric-coated pellets can be filled into capsules or incorporated into granules and sachets. The design must control pellet-size distribution, coating weight gain, gastric resistance and intestinal release.

Is sodium carbonate necessary in every pantoprazole formulation?

No. An alkaline stabilizer is common but not mandatory in every composition. The formulation must demonstrate adequate stability through its selected excipient system, manufacturing process and packaging configuration.

Can pantoprazole delayed-release tablets be made with an aqueous coating process?

Yes. Aqueous methacrylic acid copolymer systems can be used when the drug core, seal coat and process conditions protect the active ingredient from moisture-related degradation.

Are pantoprazole excipient patents likely to block generic entry?

Usually not across the entire market. A narrowly drafted formulation or process patent may affect a specific product, but competitors may design around the claim with different excipients, coating polymers or process parameters.

What packaging is most suitable for pantoprazole delayed-release tablets?

Moisture-protective blister packaging or high-barrier bottles are generally suitable. The final choice depends on water-vapor transmission, stability data, desiccant use, packaging cost and distribution conditions.

References

U.S. Food and Drug Administration. (2023a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Food and Drug Administration. (2023b). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/

U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

Wyeth Pharmaceuticals. (2012). Protonix (pantoprazole sodium) delayed-release tablets and oral suspension prescribing information. U.S. Food and Drug Administration.